New PrEP Product Implementation Roadmap for PrEP vaginal ring and CAB for PrEP in Uganda

17 February 2023

This presentation outlines the timelines for implementation of the dapivirine vaginal ring and cabotegravir (CAB) for PrEP in Uganda.

Featured Resources

Document

Coordinating Implementation Science for CAB for PrEP: Linking Modellers with the Latest Implementation Science Evidence, March 2024

This document summarises key takeaways from a March 2024 BioPIC Think Tank to ensure modellers and implementation science researchers remain aligned on the latest cabotegravir for PrEP data and evidence.

Document

Coordinating Implementation Science: Taking Stock of PrEP Evidence

This document summarises key takeaways from the BioPIC Think Tank held in March 2024 to review existing PrEP evidence and evidence gaps to date.

Document

Opportunities for Pharmacist-Delivered Injectable PrEP in the USA

These Quick Take briefings from Georgetown University’s O’Neill Institute for National and Global Health Law provide insights on barriers and opportunities for pharmacist-administered injectable PrEP in the USA, including delivery via mobile pharmacies.

Document

PrEP Ring for Adolescent Girls and Youth Women: Summary of research findings

This brief outlines findings from a recent study which has published critical new data on use of the dapivirine vaginal ring (PrEP ring or ring) among adolescent girls and young women in eastern and southern Africa, offering evidence that the ring is safe, effective, and highly acceptable.

Presentation

PrEP Ring Safety Data in Adolescent Girls and Youth Women (AGYW)

This slide deck presents emerging evidence to support conversations on expanding pre-exposure prophylaxis (PrEP) ring access for adolescent girls and young women (AGYW) in policy and programmatic rollout.

Document

PrEP Ring for Pregnant and Breastfeeding Women: Summary of research findings in eastern and southern Africa

This brief outlines findings from recent studies which have published critical new data on use of the dapivirine vaginal ring (PrEP ring or ring) among pregnant and breastfeeding people in eastern and southern Africa, offering evidence that the PrEP ring is a safe and effective HIV prevention method for a broader population than was initially…

Presentation

PrEP Ring Safety Data in Pregnant and Breastfeeding Women

This slide deck presents emerging evidence to support conversations on expanding pre-exposure prophylaxis (PrEP) ring access for pregnant and breastfeeding women (PBFW) in policy and programmatic rollout.

Spreadsheet

MOSAIC – PrEP Site Implementation and New Product Readiness Assessment Tool

This tool is intended to provide insight into the current state of PrEP services and to identify critical barriers and facilitators to PrEP implementation. Additionally, this tool is designed to inform preparations for new PrEP product introduction (CAB PrEP, PrEP ring, or both) according to national priorities. Findings from readiness assessment visits using this tool…

PrEP for Pregnant and Breastfeeding People: Advocacy, Policy, and Programmatic Tools

Evidence shows that offering PrEP is a safe and effective HIV prevention strategy for pregnant and breastfeeding people. Guidance from the World Health Organization (WHO) supports provision of PrEP to pregnant and breastfeeding people (PBFP) who are at continuing substantial risk of HIV infection. Evidence has shown that people have an increased need for HIV…

Document

Private Sector Market Assessment: Eswatini

This market assessment explores the opportunities and barriers to leveraging private sector channels to expand access to new and existing pre-exposure prophylaxis (PrEP) methods, including oral PrEP, the dapivirine vaginal ring (PrEP ring), and long acting cabotegravir (CAB PrEP) in Eswatini.